Children's Hospital is part of the UPMC family.
Our Sites
Be safe anytime, anywhere.
To find a pediatrician or pediatric specialist, please call 412-692-7337 or search our directory.
A resource for our network of referring physicians.
For more information about research, please call our main office at 412-692-6438.
Ranked #8 Nationally by U.S. News & World Report.
A study conducted at Children’s Hospital of Pittsburgh of UPMC shows that early and aggressive medication treatment did not preserve the body’s ability to make insulin in high-risk obese youth with type 2 diabetes.
The findings were published online today in Diabetes Care and the results will be presented this week at the American Diabetes Association Scientific Sessions in Orlando, Florida.
The study included 91 youth partcipants ages 10 to 19, part of the larger Restoring Insulin Secretion (RISE) study. To determine if early, aggressive treatment would improve outcomes, participants at four study sites were randomly assigned to one of two treatment groups.
The first group received three months of glargine—a long-acting insulin—followed by nine months of metformin. The second group received only metformin for 12 months. Participants were then monitored for three more months after treatment ended.
The RISE pediatric medication study found that beta cell function—key to the body’s ability to make and release insulin—declined in both groups during treatment and worsened after treatment ended.
“I am not entirely surprised with the outcome of RISE not only because the disease appears to be more severe in youth, but because its pathogenetic mechanisms also are worse even in the stage of prediabetes,” said Silva Arslanian M.D., pediatric endocrinologist and diabetologist, scientific director, Center for Pediatric Research in Obesity and Metabolism, and principal investigator of RISE.
Children’s Hospital was one of four sites that conducted the RISE pediatric medication study; the others were Children’s Hospital Colorado, Indiana Universtiy and Yale University.
National Institutes of Health support for RISE comes primarily through National Institute of Diabetes and Digestive and Kidney Diseases grants U01DK94430, U01DK94431, U01DK94406, U01DK94438 and U01DK094467, with additional support from the National Center for Advancing Translational Sciences.
The Department of Veterans Affairs, Kaiser Permanente Southern California, and the American Diabetes Association also support the studies, with additional donations of supplies from Allergan Corporation, Apollo Endosurgery, Abbott Laboratories, and Novo Nordisk A/S.
For more information about this study, please contact a member of the RISE study team at 412-692-5846 or visit www.chp.edu/rise.
Contact: Andrea Kunicky Office: 412-692-6254 Mobile: 412-439-5264 E-mail: Andrea.Kunicky@chp.edu
Contact: Marc Lukasiak Office: 412-692-7919 Mobile: 412-721-2120 E-mail: Marc.Lukasiak@chp.edu
Children's Hospital's main campus is located in the Lawrenceville neighborhood. Our main hospital address is:
UPMC Children’s Hospital of Pittsburgh One Children’s Hospital Way 4401 Penn Ave. Pittsburgh, PA 15224
In addition to the main hospital, Children's has many convenient locations in other neighborhoods throughout the greater Pittsburgh region.
With MyCHP, you can request appointments, review test results, and more.
For questions about a hospital bill call:
To pay your bill online, please visit UPMC's online bill payment system.
Interested in giving to Children's Hospital? Support the hospital by making a donation online, joining our Heroes in Healing monthly donor program, or visiting our site to learn about the other ways you can give back.